Table 4.
Clinical trials of DNMTis combined with immunotherapy in NSCLC.
| Inhibitor target | Inhibitor (name) | Study type | Status | Clinical trial number |
|---|---|---|---|---|
| DNMT + PD-1 + CDA | Decitabine + Nivolumab +THU | Phase 2 | Completed | NCT02664181 |
| DNMT + HDAC + PD-1/PD-L1 | Azacitidine + Entinostat + ICIs | Subsequent study of a phase 2 trial | Completed | (146) |
| DNMT + PD-1 | CC-486 + Pembrolizumab | Phase 2 | Active, not recruiting | NCT02546986 |
| DNMT + PD-1 | Guadecitabine + Pembrolizumab | Phase 1 | Active, not recruiting | NCT02998567 |
| DNMT + HDAC + PD-1 | Azacitidine + Entinostat + Nivolumab | Phase 2 | Active, not recruiting | NCT01928576 |
| DNMT + HDAC + PD-1 | Guadecitabine + Pembrolizumab + Mocetinostat | Phase 1 | Active, not recruiting | NCT03220477 |
| DNMT + PD-1 + CDA | Decitabine + Pembrolizumab + THU | Phase1/2 | Recruiting | NCT03233724 |
| DNMT + CTLA-4 + PD-1 | Guadecitabine + Ipilimumab + Nivolumab | Phase 2 | Not recruiting | NCT04250246 |
| DNMT + PD-1 | Decitabine + Camrelizumab | Case report | Completed | (148) |
| DNMT + IDO-1 + PD-1 | Azacitidine + Epacadostat + Pembrolizumab | Phase1/2 | Completed | NCT02959437 |
DNMT, DNA methyltransferases; CDA, cytidine deaminase; THU, tetrahydrouridine; ICIs, immune checkpoint inhibitors; IDO-1, indoleamine 2,3-dioxygenase; HDAC, histone deacetylase; CTLA-4, cytotoxic T lymphocyte-associated antigen.